anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cervical cancer-related stigma is common but understudied in the Caribbean. This study aims to describe the age difference of cervical cancer stigma and to evaluate the influence on the prevention practices among the Caribbean nonpatient population in Jamaica, Grenada, and Trinidad and Tobago.
METHODS: A cross-sectional study involving 1209 participants was conducted using a culturally trans-created Cancer Stigma Scale for the Caribbean context and supplemented with questions on cervical cancer and human papillomavirus (HPV) and HPV vaccine knowledge and beliefs. Descriptive analyses and χ2 tests were conducted.
RESULTS: The χ2 tests showed age is statistically significantly related to participants' response to stigma items such as "community members believe cervical cancer is viewed as shameful" (P = .0001); "women with cervical cancer are treated with less respect than usual by others" (P < .0001); "women with cervical cancer are rejected by family members" (P = .0007); "women with cervical cancer are rejected by intimate partners" (P < .0001); and "intimate partners blame women for having cervical cancer" (P = .0032). Additionally, age has statistically significant associations with endorsements of negative views of cervical cancer from the community (P < .0001) and family (P < .0001) as key barriers to cervical cancer care (item: "discourage women from seeking and obtaining screening and treatment"). Notably, younger respondents (18-25 years) are more sensitized to the unfair stigma and hold more stigma.
CONCLUSIONS: Among Caribbeans, age influences cervical cancer stigma. Younger persons acknowledged greater stigma within families and communities. This study can guide age-informed interventions and programs to reduce stigma and improve cervical cancer screening and care seeking to reduce cervical cancer burden and disparities.
The application provides an ointment for treating burns and scalds and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions. The ointment comprises the following raw materials: gypsum Fibrosum Preparatum, rhizoma Bletillae, radix Ampelopsis, mirabilitum Crystallina, borneolum Syntheticum, sanguis Draxonis, calomelas, hydrargyri oxydum rubrum, os Draconis, and adeps Sus Domestica. The preparation method comprises the following steps: heating the lard to refine the lard, filtering and cooling to obtain lard; pulverizing Gypsum Fibrosum Preparatum, rhizoma Bletillae, radix Ampelopsis, mirabilitum crystallina, borneolum Syntheticum, sanguis Draxonis, calomelas, rad mercuric oxide and Os Draconis, mixing with the above lard, and stirring. The application adopts calcined gypsum, bletilla striata and hydrargyri oxydum rubrum to astringe and stop bleeding, prevent corrosion and promote tissue regeneration, and is matched with calomel to counteract poison and kill poison, heal wound and diminish inflammation; along with the infiltration of the medicine at the wound, ampelopsis japonica and gypsum rubrum play roles of clearing away heat and toxic material, purging fire, matching borneol and dragon's blood to activate blood and alleviate pain, and dragon's bone is added to relieve mental uneasiness. The wound surface is subjected to pain relieving, hemostasis and recovery from inside to outside. The lard is added into the raw materials, so that the skin-care cream has the advantages of moistening and nourishing and promoting the skin to recover elasticity.
A 76-year-old woman was diagnosed with invasive bladder cancer and underwent cystectomy, bilateral external iliac, internal iliac and obturator lymph node dissection, and bilateral cutaneous ureterostomy. Pathological findings showed no lymph node metastasis ; however, the patient had lower abdominal pain and fever from the 14th postoperative day, and computed tomography (CT) revealed fluid retention in the pelvis. Retrograde pyelography showed no leakage from the urinary tract, and a drain was placed after percutaneous puncture of the pelvic cavity. There was copious drainage fluid and its nature and composition suggested lymphorrhea. Ultrasound-guided intranodal lymphangiography revealed contrast material leakage from the bilateral lymph node dissection sites. After lymphangiography, drainage from the drain decreased. Despite the drainage being minimal yet persistent, sclerotherapy was performed, the drain was removed and the patient was discharged. After discharge, there was leakage from the site of urethral extraction, and CT revealed recurrent lymph leakage. The patient was readmitted, and a second lymphangiography was performed. The leakage from the site of urethral extraction gradually decreased, and the patient was discharged on the 59th postoperative day. CT after discharge confirmed that the lymphorrhea had shrunk in size, and there has been no recurrence since then. Lymphangiography is a promising treatment option for lymphorrhea after pelvic surgery.
<P>PROBLEM TO BE SOLVED: To provide a composition which effectively prevents and cures diseases caused by immune abnormality such as allergic diseases, has few side effects, is safe and easy to drink or ingest, and has an immunomodulating function, and to provide foods and drinks or a material for foods and drinks using the composition.  <P>SOLUTION: The immunomodulating compositon comprises at least one of (A) and (B). The foods and the drinks or a material for foods and drinks contain the composition. (A): Lactococcus lactis subsp. cremoris FC, FERM AP-20185 having an ability to induce the production of interleukin 10 and interleukin 12 from at least one of the dendritic cells and the spleen cells of mammals. (B): Polysaccharides produced by (A).  <P>COPYRIGHT: (C)2010,JPO&INPIT
Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
Patients with baseline PET scan assigned to this Arm will receive two cycles of 3-weekly schedule of induction chemotherapy with paclitaxel/cisplatin (TP), consisting of paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (\<35% decrease in SUVmax) crossed over to FOLFOX regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
BACKGROUND: Guillain-Barré syndrome (GBS) is an autoimmune disorder characterized by demyelination of peripheral nerves. GBS-associated posterior reversible encephalopathy syndrome (PRES) is a rare and potentially life-threatening complication in the pediatric population. We aimed to report and analyze the clinical features, management, and outcomes of three cases of GBS-associated PRES in our setting in the light of the existing literature.
METHODS: Medical records of 75 pediatric patients with GBS were reviewed for autonomic changes and GBS-associated PRES. Thirty-one developed dysautonomia while three were identified to have PRES. Clinical, radiological, laboratory, and treatment data were collected and analyzed.
RESULTS: All three patients were male and presented with symptoms of acute flaccid paralysis and respiratory distress requiring mechanical ventilation. All three patients experienced various complications, including hypertension, seizures, and hyponatremia, and were subsequently diagnosed with PRES. Multimodal intensive care resulted in patient improvement and discharge in an ambulatory state after an average of 104 days of care.
CONCLUSIONS: GBS-associated PRES is a rare and potentially life-threatening complication that can occur in pediatric patients with GBS. Our findings suggest that early recognition, prompt intervention, and multimodal intensive care can improve patient outcomes. Further studies are needed to determine optimal treatment strategies for GBS-associated PRES.
After registering participant's randomization will be done through sealed envelope method and will be allocated in both groups equally. Group 1 will receive passive static stretching while group 2 will receive active static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters. Group 1 groups will perform passive static stretching and group 2 will perform active static stretching. At the end of the intervention participants will be assessed again using the same parameters. Statistical analysis will be carried out to compare the outcomes measures of both groups.
Patients will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor. Upon HSC engraftment, patients will be treated with escalating doses of the anti-CD33 antibodydrugconjugate Gemtuzumab-Ozogamicin (GO). A conditioning regimen containing GO (d-14, d-11, d-8), Fludarabine 30 mg/m2 (d-6 to d-3) and Melphalan 140mg/m2 (d-2) is used prior to transplantation.
The primary goal of the study is to assess the effect of heavy drinking on next day academic performance. A placebo-controlled 2-period crossover design will be used to compare the effects of dosing status on academic performance, with participants serving as their own controls. Participants are dosed on two separate occasions, once with non-alcoholic beverage and the other time with alcoholic beverage sufficient to raise blood alcohol to 0.10 g%. The morning after dosing, participants' academic performance is measured using a standardized achievement test (Graduate Record Exam). Participants' cognition is tested using the the Psychomotor Vigilance Test (PVT). Data on participants' demographics, family history of drinking problems and alcohol use. We are also collecting information on hangover symptoms and sleep quality the morning after dosing, in addition to participants' self ratings of academic performance. The procedure is conducted twice with one week in between, switching the individuals' dosing status, presenting a different, but comparable lecture and reading, and administering a different quiz based on the new lecture and reading and a different, but comparable standardized achievement exam. This design is intended to test the hypothesis that intoxication (0.10 g% BAC) with alcoholic beverage impairs next-day academic performance.

Participation involves a total of five sessions over a two week period. Participants are undergraduates who volunteer and meet inclusion criteria. Prior to enrollment, volunteers are screened to ensure they meet initial eligibility criteria. Eligible volunteers receive written instructions regarding participation and are scheduled for the study sessions. Participants report to the study site on the first session for an additional screening by the study physician and go through the informed consent process. Eligible participants report back the next week for their first dosing night where they receive several drinks (alcohol or placebo) sufficient to raise their Breath Alcohol Level (BrAC) to 0.10 g%; the amount of beverage administered is based on their body weight. Those receiving placebo receive the same total quantity of beverage as those receiving alcohol. Both alcohol-dosed and placebo-dosed participants are breath-tested after they have completed their required dose. Participants sleep at the study site and are monitored overnight. The next morning they are awakened and are escorted to the exam room for the performance trials. They return the next week for the second dosing night/dosing morning, and receive either alcohol or placebo, depending on what was administered the previous week, and take different but comparable performance tests.
Techniques for managing encoded communications for medical devices in a clinical environment are provided. Different versions of signal coding libraries are generated for different devices in a communication path. A first signal coding library may be generated using a first signal definition that includes a set of fields. A second signal coding library may be generated using a second signal definition that includes a subset of the fields of the first signal definition, and excludes one or more of the fields of the first signal definition. A message encoded using the first signal coding library may not be completely decodable using the second signal coding library. By selectively deploying the signal coding libraries to different systems, devices, and components in a clinical environment, access to information in message fields can be effectively managed.
Childhood obesity, with its metabolic complications, is a problem of public health. The International Diabetes Federation (IDF) has recommended glucose levels 1 h post oral glucose load (1h-PG) > 155-209 mg/dL as diagnostic for intermediate hyperglycemia (IH), while >209 mg/dL for type 2 diabetes (T2D). The aim of the study was to assess the occurrence of prediabetes, IH, and T2D in children and adolescents with simple obesity according to the criteria of American Diabetes Association (ADA) and of IDF, and the effect of COVID-19 pandemic on these disorders. Analysis included 263 children with simple obesity, screened either in prepandemic (PRE-113 cases) or post-pandemic period (POST-150 cases). All children underwent 2 h OGTT with measurements of glucose and insulin every 0.5 h, lipid profile, and other tests; indices if insulin resistance (IR): HOMA, QUICKI, Matsuda index, AUC (glu/ins) were calculated. The incidence of T2D, prediabetes, and IH was higher in POST with respect to PRE, with significant differences in the indices of IR, except for HOMA. Significant differences were observed in the assessed parameters of glucose metabolism among the groups with T2D, prediabetes, IH, and normal glucose tolerance (NGT), with some similarities between IH (based on 1h-PG) and prediabetes. Increased frequency of dysglycemia among children and adolescents with simple obesity is observed after COVID-19 pandemic. Metabolic profile of patients with IH at 1h-PG is "intermediate" between NGT and prediabetes.
The present invention relates to animal cartilage health care capsule and its prepn. method. The capsule filler mainly is animal cartilage powder, supplemented with medical vitamin in an amount of 0-30% of the total wt. of filler. The prepn. method is that the animal cartilage is dried, ground, sterilized, mixed with other components, further sterilized and packaged. The invented health care capsule can inhibit tumour growth, anti senility, and possesses the health care function to cardiovascular system. It is simple in prepn. method.
A composition comprising lactoferrin and kappa- (κ) carrageenan for use in the treatment of and/or prevention of dysbiosis in a subject, is provided. Preferably the composition comprises lactoferrin in a range of 5µg/ml to 50µg/ml, and κ-carrageenan in a range of 5µg/ml to 50µg/ml. A composition comprising lactoferrin and kappa-carrageenan for use in the prevention of qualitative-quantitative type alterations of the physiological vaginal microbiota, wherein the alterations are capable of causing infections and inflammatory process is also outlined. Preferably the composition is for use in the treatment of vaginal or cervical-vaginal infections, particularly vaginitis, vaginosis, herpes simplex, papilloma virus (HPV) or thrush. The composition is suitable for vaginal administration preferably as a personal lubricant. A device for use in the prevention and/or treatment of vaginal and cervical-vaginal infections wherein the device comprises the lactoferrin and kappa-carrageenan composition is provided. The device is preferably a vaginal pessary, vaginal suppository, a tampon, a contraceptive, a spatula, or an intimate toy, wherein the device is coated or impregnated with the composition.
An orally administrable pharmaceutical dose unit, such as a tablet or capsule, has a size greater than 7 mm and comprises a drug and an outer coating, which coating comprises a polymer material that is insoluble in aqueous solutions with a pH below 4.0 (ie under the acid conditions present in the human stomach). By appropriate selection of the components and thickness of the coating, it is possible for such dose units to be retained intact within the stomach, following their co-administration with a meal, with the dose unit only breaking up to release the drug contained therein when the bulk of the food has emptied into the small intestine. The coating is thus adapted to provide a separation of the dose unit from co-administered food material and disintegration of the dose unit in the stomach, thereby reducing adverse interaction between drug and food. A fail-safe mechanism is provided when the polymer begins to dissolve at a higher pH that is typical of the small intestine (ie pH 5.0 and above). Prefered polymers are enteric polymers such as cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), ethyl cellulose and enteric methacrylic acid copolymers (such as 1: 1 copolymer of methacrylic acid and ethyl acrylate). Suitable drugs for use in the dose units include amoxicillin, ampicillin, antipyrine, clodronate and other similar bisphosphonates, ACE inhibitors such as captopril, cilazipril, enalapril, fosinopril, lisinopril, mocxipril, perindopril, quinapril, ramipril and trandolapril, cephalexin, ketoconazole, oxytetracycline, tetracycline, levodopa, methyldopa, methacycline, nafcillin, penicillamine, rifamycin, theophylline, peptidomimetic thrombin inhibitors, such as sampatrilat, and the peptide inhibitor LY303496.
BACKGROUND: In the ongoing battle against BCR-ABL+ leukemia, despite significant advances with tyrosine kinase inhibitors (TKIs), the persistent challenges of drug resistance and the enduring presence of leukemic stem cells (LSCs) remain formidable barriers to achieving a cure.
METHODS: In this study, we demonstrated that Disulfiram (DSF) induces ferroptosis to synergize with TKIs in inhibiting BCR-ABL+ cells, particularly targeting resistant cells and LSCs, using cell models, mouse models, and primary cells from patients. We elucidated the mechanism by which DSF promotes GPX4 degradation to induce ferroptosis through immunofluorescence, co-immunoprecipitation (CO-IP), RNA sequencing, lipid peroxidation assays, and rescue experiments.
RESULTS: Here, we present compelling evidence elucidating the sensitivity of DSF, an USA FDA-approved drug for alcohol dependence, towards BCR-ABL+ cells. Our findings underscore DSF's ability to selectively induce a potent cytotoxic effect on BCR-ABL+ cell lines and effectively inhibit primary BCR-ABL+ leukemia cells. Crucially, the combined treatment of DSF with TKIs selectively eradicates TKI-insensitive stem cells and resistant cells. Of particular note is DSF's capacity to disrupt GPX4 stability, elevate the labile iron pool, and intensify lipid peroxidation, ultimately leading to ferroptotic cell death. Our investigation shows that BCR-ABL expression induces alterations in cellular iron metabolism and increases GPX4 expression. Additionally, we demonstrate the indispensability of GPX4 for LSC development and the initiation/maintenance of BCR-ABL+ leukemia. Mechanical analysis further elucidates DSF's capacity to overcome resistance by reducing GPX4 levels through the disruption of its binding with HSPA8, thereby promoting STUB1-mediated GPX4 ubiquitination and subsequent proteasomal degradation. Furthermore, the combined treatment of DSF with TKIs effectively targets both BCR-ABL+ blast cells and drug-insensitive LSCs, conferring a significant survival advantage in mouse models.
CONCLUSION: In summary, the dual inhibition of GPX4 and BCR-ABL presents a promising therapeutic strategy to synergistically target blast cells and drug-insensitive LSCs in patients, offering potential avenues for advancing leukemia treatment.
PURPOSE OF REVIEW: The purpose of this review is to summarize the very recent literature surrounding hearing outcomes of children with congenital cytomegalovirus (cCMV) detected through systematic screening programs.
RECENT FINDINGS: There are several different approaches to cCMV screening including forms of targeted vs. universal screening of newborns as well as maternally-derived prenatal testing. However, many studies fail to document hearing-related outcomes both in the newborn period and further into childhood when late-onset sensorineural hearing loss (SNHL) can occur. This systematic review included studies of neonates screened for cCMV reporting hearing outcomes for at least one point in time. Hearing targeted screening appeared the most widely reported for detection of unilateral and bilateral SNHL in those with cCMV. A few studies examined these clinical findings in relation to antiviral treatment.
SUMMARY: Congenital CMV is an important and common cause of childhood hearing loss. Newborn screening programs may expand opportunities for early diagnosis and treatment of the infection and its sequelae.
INTRODUCTION: Present study attempted to analyze seizure freedom and detailed functional outcomes after functional hemispherotomy and utility of hemispherotomy outcome prediction scale (HOPS) scores in predicting outcomes.
METHODS: Patients who underwent functional hemispherotomy were analyzed for clinical presentation, neuroimaging, seizure outcomes, and functional outcomes.
RESULTS: A total of 76 procedures were performed on 69 patients. Mean age at the surgery was 8 ± 6.1 years. Fourteen patients were < 2 years. Age of onset epilepsy of the cohort was 2.0 ± 3.3 years. All had severe catastrophic epilepsy with multiple daily seizures. All patients had motor deficits with 36 (52%) patients had contralateral dysfunctional hand. Perinatal stroke (49%) was most common substrate followed by cortical malformations (21.7%). Eight patients had contralateral imaging abnormalities. Fifty-nine (86.76%) patients remained seizure free (Engle 1a) at 41 + -20.9 months. HOPS scores were available for 53 patients and lowest seizure outcome was 71% for HOPS score of 4. Lower HOPS scores predicted better seizure outcomes. Cortical malformations operated earlier than 2 years predicted poor seizure outcomes (66.6%). Positive functional outcomes are recorded in 80% of patients with 78% reporting improvement from the pre-surgical level. Five (7.2%) patients underwent shunt surgery. One mortality recorded.
CONCLUSIONS: Hemispherotomy has excellent seizure outcomes. Early surgery in cortical malformations appears to be predictor of poorer seizure outcomes. HOPS score is a good tool to predict the seizure outcomes. Hemispherotomy is perceived to improve the Cognitive and functional performance.